http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sang Hoon Ahn ),( Won Hyeok Choe ),( Yoon Jun Kim ),( Jeong Heo ),( Dorota Latarska-smuga ),( Jiho Kang ),( Seung Woon Paik ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Chronic Hepatitis C Virus (HCV) infection increases the risk for progressive liver disease, hepatocellular carcinoma and negatively impacts the patient’s quality of life. HCV treatment is evolving with direct acting antivirals but IFN based therapy has been the standard of care for many years and remains available in some countries. The MOSAIC study aims to characterize patients with chronic HCV infection and assess the impact of IFN-containing treatment on health-related quality of life, work related productivity and health care utilization. Methods: MOSAIC is an international prospective multicenter observational study that has been conducted in 20 countries. Consecutive patients with chronic HCV infection were enrolled and those who initiated an IFN based regimen were prospectively followed for 48 weeks. We report results from the Korean cohort Results: 100 patients were enrolled: 86 were treatment naïve and 14 were treatment experienced. 33 patients initiated an IFN based regimen: 6 patients started IFN + RBV, 26 patients started Peg-IFN + RBV, none started Peg-IFN + RBV + DAA and 1 patient received other treatment. Among the treated cohort, demographic and disease characteristics were the following: the mean age was 54.5 years; 14 patients were male. 14 had minimal or no fibrosis, 2 portal fibrosis, 3 bridging fibrosis and 6 patients suffered from cirrhosis. HCV Genotype distribution was as follows: genotype 1: 11; genotype 2: 19 and genotype 3: 3. Table 1 describes the results at baseline and changes over 4, 12 and 48 weeks and end-of-treatment (EOT) for the quality of life and work productivity outcome measures (EQ-5D-5L, HCV-PRO and WPAI). Conclusions: Results from the Korean cohort of the MOSAIC study show a moderate trend for deterioration of health-related quality of life and work productivity associated with IFN based treatment for patients with chronic HCV infection during treatment period. Acknowledgements: The design, study conduct, analysis, and financial support of MOSAIC study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the content of the abstract. All authors had access to all relevant data and participated in writing, review, and approval of this abstract. Medical writing support was provided by Olivier Van de Steen of Medeor-consulting, funded by AbbVie. Disclosures: Sang Hoon Ahn: served as an advisor and lecturer for Bristol-Myers Squibb, Gilead Sciences, F.Hoffmann-La Roche, Merck, AbbVie, and has received unrestricted grants from Bristol-Myers Squibb, Gilead Sciences, and F. Hoffmann-La Roche for investigator- initiated trials Won Hyeok Choe: Nothing to disclosure Yoon Jun Kim: Nothing to disclosure Jeong Heo: received a grant from GSK; Research support from BMS, and Roche; Advisor for Abbvie, BMS, Gilead Sciences, Pharma Essentia, SillaJen, and Johnson & Johnson. Dorota Latarska-Smuga, Jiho Kang: are employees of AbbVie, Inc. and may hold stock or stock options. Seung Woon Paik: received grant and research support from AbbVie, BMS, Gilead, GSK, Merck, Novartis, and Roche
Combined Cis-platinum and Alpha Interferon Therapy of Advanced Hepatocellular Carcinoma
( Sang Keun Ji ),( Neung Hwa Park ),( Hyun Mook Choi ),( Young Woo Kim ),( Sin Hwa Lee ),( Keum Hee Lee ),( Su Yul Ahn ),( Sang Uk Lee ),( Byung Hoon Han ),( Byung Chae Park ) 대한내과학회 1996 The Korean Journal of Internal Medicine Vol.11 No.1
( Sang Hoon Ahn ),( Hyun Woong Lee ),( Yong Soo Kim ),( Ja Kyung Kim ),( Kwang Hyub Han ),( Chae Yoon Chon ),( Young Myoung Moon ) 대한소화기기능성질환·운동학회 2009 Gut and Liver Vol.3 No.1
Background/Aims: Interferon beta (IFN-β) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-β (IFN-β-1a) plus oral ribavirin versus interferon alpha (IFN-α) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naive patients were randomized into two equal-sized treatment groups. Both IFN-β-1a (44μg) and IFN-α (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-β-1a group and IFN-α groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-β-1a group than in the IFN-α group, and there were more HCV genotype 1 patients in the IFN-β-1a group (eight versus seven). The IFN-β-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-β-1a and ribavirin and that of IFN-α and ribavirin. (Gut and Liver 2009;3:20-25)
Ahn, Sung-Hoon,Heo, Tae-Hwe,Jun, Hyun-Sik,Choi, Yongseok Asian Australasian Association of Animal Productio 2020 Animal Bioscience Vol.33 No.4
Objective: Interleukin-6 (IL-6) is a T cell-derived B cell stimulating factor which plays an important role in inflammatory diseases. In this study, the pharmacokinetic properties of LMT-28 including physicochemical property, in vitro liver microsomal stability and an in vivo pharmacokinetic study using BALB/c mice were characterized. Methods: LMT-28 has been synthesized and is being developed as a novel therapeutic IL-6 inhibitor. The physicochemical properties and in vitro pharmacokinetic profiles such as liver microsomal stability and Madin-Darby canine kidney (MDCK) cell permeability assay were examined. For in vivo pharmacokinetic studies, pharmacokinetic parameters using BALB/c mice were calculated. Results: The logarithm of the partition coefficient value (LogP; 3.65) and the apparent permeability coefficient values (P<sub>app</sub>; 9.7×10<sup>-6</sup> cm/s) showed that LMT-28 possesses a moderate-high cell permeability property across MDCK cell monolayers. The plasma protein binding rate of LMT-28 was 92.4% and mostly bound to serum albumin. The metabolic half-life (t<sub>1/2</sub>) values of LMT-28 were 15.3 min for rat and 21.9 min for human at the concentration 1 μM. The area under the plasma drug concentration-time curve and C<sub>max</sub> after oral administration (5 mg/kg) of LMT-28 were 302±209 h·ng/mL and 137±100 ng/mL, respectively. Conclusion: These data suggest that LMT-28 may have good physicochemical and pharmacokinetic properties and may be a novel oral drug candidate as the first synthetic IL-6 inhibitor to ameliorate mammalian inflammation.
A case of angular pregnancy: Is the expectant management possible?
( Sung Hye Jeon ),( Ho Yeon Kim ),( Geum-joon Cho ),( Soon-cheol Hong ),( Min-jeong Oh ),( Hai-joong Kim ),( Ki Hoon Ahn ) 대한산부인과학회 2018 대한산부인과학회 학술대회 Vol.104 No.-
Angular pregnancy is defined as implantation of the embryo just medial to the uterotubal junction, in the lateral angle of the uterine cavity and medial to the round ligament. It should be distinguished from interstitial pregnancy because the management of the patient varies according to the diagnosis and it can be emergency conditions. A 29-year-old, parity 0-0-0-0 woman visited our hospital for a routine antenatal examination at 5 weeks and 5 days of gestation. She denied any abnormal medical and surgical histories. Transvaginal sonography showed a gestational sac without fetal heart beat located in the left lateral angle in the uterine cavity. It was difficult to differentiate the cornual pregnancy from interstitial ectopic pregnancy. Initial hCG level at the first visit was 10001.1 mIU/mL. For detailed information, MRI images were obtained at 6 weeks and 4 days of gestation. The radiologic finding was more suspicious of angular pregnancy and the radiologist recommended further observation if clinically indicated. At 7 weeks and 6 days of gestation, fetal heartbeat was confirmed by transvaginal sonography. The pregnant woman had mild lower abdominal cramps and intermittent vaginal spotting which might be a sign of complication that needs surgical treatment. Otherwise, antenatal tests were normal. At the present time of this report, the gestational age is 24 weeks and 1 days and the fetal viability is expected. She does not have any abnormal symptoms and signs. Sonography shows normal uterus shape without protrusion of uterine angle, and fetal development is also within normal range. The thickness of the myometrium is maintained above 3 mm. We report a rare case of angular pregnancy that is being successfully maintained with a literature review. Our case shows that in case of cornual pregnancy suspicious of angular pregnancy, an expectant management with close observation needs to be considered as a treatment option.
Anti-tumor Activity of Novel Indirubin Derivatives in Rat Tumor Model
Sang Gun Ahn,Soo A Kim,Hyun Woo Kim,Young Ho Woo,Jung Hoon Yoon 대한구강악안면병리학회 2005 대한구강악안면병리학회지 Vol.29 No.5
lndil‘ ubin is the active ingredient of Danggui Longhui Wan‘ a mixture of herbal medici l1e t hat is used to treat chronic myelocytic leukemia in tradi t ional Chinese medicine‘ He re, we show that new indirubin deri vatives 5' -ni tro-indirubinoxime, 5' -f1 uoro-indiru binoxime and 5’ -tri rnethylacetamino-i nd i 1'1.1 bi noxi me‘ have potent a n ti- proliferative activity on various human cancer cells and oncogenic RK3E-ras rat kidney cells with lC50 con centration ranging from 1-25 μ M, When the RK3E-ras cells were treated with indirubin derivatives for 24 h, the activity of caspase-3 and caspasc-7 was induccd followed by apoptosis , 011 the other hand, the activity of SAPK/JNK was inhi bited over the same period , lndirubin deri vatives a lso s howed strong ant i-tumor activity in rat s이 id and oral tumor models The inhibition of tlUl10r g:rowth was observed in animals beaJ‘ing RK3E-ras-induced turnor given subcutaneous dose of 100 mg/kg every other day for 10 days, Histologically, μeatment of indirubin derivatives caused significant inhibition of tumor formation associated wi th increased apoptosis and decreased proliferation of tumor cell s , These findings provide the potential value of indirubin derivatives as a novel candi date fOl 없l tJ -cancer agents ,